Kazia Therapeutics Limited (KZIA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kazia Therapeutics Limited (KZIA) Healthcare & Pipeline Overview

Kazia Therapeutics Limited is an oncology-focused biotechnology firm developing innovative anti-cancer drugs, including Paxalisib for glioblastoma, positioning them within the competitive biotechnology landscape. With a focus on brain-penetrant inhibitors, Kazia aims to address unmet needs in cancer treatment, operating from its base in Sydney, Australia.

What Is the Investment Thesis for KZIA?

Kazia Therapeutics presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The primary value driver is the clinical progress of Paxalisib, particularly in glioblastoma. Positive clinical trial results could lead to significant upside potential. The company's small market capitalization of $17.7M reflects both the potential and the risks associated with its pipeline. Key catalysts include upcoming data readouts from ongoing clinical trials of Paxalisib and EVT801. Risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development. The company's negative P/E ratio of -0.81 and a profit margin of -48583.0% highlight its current lack of profitability, underscoring the reliance on future clinical and commercial success.

Based on FMP financials and quantitative analysis

KZIA Key Highlights

Market capitalization of $17.7M reflects the company's small size and early stage of development.

• Gross margin of 100.0% indicates strong potential profitability if products reach commercialization, though this is currently based on limited revenue streams.
• Negative P/E ratio of -0.81 highlights the company's current lack of profitability.
• Profit margin of -48583.0% underscores significant R&D expenses relative to revenue.
• Beta of 1.63 suggests higher volatility compared to the overall market, typical for biotechnology stocks.

Who Are KZIA's Competitors?

KZIA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KZIA's Key Strengths?

Focus on brain-penetrant drugs for brain cancers.

• Lead candidate Paxalisib targeting glioblastoma.
• Experienced management team with expertise in drug development.
• Lean operational structure with low employee count.

What Are KZIA's Weaknesses?

Limited financial resources.

• Dependence on the success of Paxalisib and EVT801.
• High attrition rate in drug development.
• Small market capitalization makes it vulnerable to market fluctuations.

What Could Drive KZIA Stock Higher?

Data readouts from ongoing clinical trials of Paxalisib in glioblastoma.

• Data readouts from ongoing clinical trials of EVT801 in various cancers.
• Potential strategic partnerships with larger pharmaceutical companies.
• Expansion of pipeline through in-licensing or acquisition.
• Regulatory submissions and approvals for Paxalisib and EVT801.

What Are the Key Risks for KZIA?

Financial-distress signal — its Altman Z-Score of -3.64 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for Paxalisib and EVT801.
• Regulatory hurdles and delays in obtaining approvals.
• Competition from other biotechnology and pharmaceutical companies.
• Need for additional capital to fund ongoing research and development.
• Intellectual property challenges and patent expirations.

What Are the Growth Opportunities for KZIA?

• Glioblastoma Treatment Market: Paxalisib's development as a treatment for glioblastoma represents a significant growth opportunity. If Paxalisib demonstrates efficacy and safety in clinical trials, it could capture a significant share of this market, providing substantial revenue potential for Kazia. The timeline for this growth opportunity is dependent on successful completion of ongoing and planned clinical trials.
• EVT801 Development: The development of EVT801, an investigational new drug for various forms of cancer, presents another growth opportunity for Kazia. While the specific target indications and market size are still being defined, successful clinical development of EVT801 could expand Kazia's pipeline and address multiple oncology markets. This growth opportunity is contingent on preclinical and clinical data supporting the drug's safety and efficacy.
• Strategic Partnerships: Kazia can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide Kazia with access to additional funding, expertise, and resources, increasing the likelihood of success. The timing and terms of any potential partnerships are uncertain, but they represent a significant potential growth driver.
• Expansion of Pipeline: Kazia can expand its pipeline through in-licensing or acquisition of additional drug candidates. This would diversify the company's portfolio and reduce its reliance on Paxalisib and EVT801. The availability of suitable drug candidates and the company's ability to secure funding for acquisitions will determine the feasibility of this growth opportunity.
• Orphan Drug Designation: Obtaining orphan drug designation for Paxalisib in glioblastoma could provide Kazia with market exclusivity and other regulatory benefits. Orphan drug designation is granted to drugs that treat rare diseases, providing incentives for companies to develop these therapies. This could enhance the commercial attractiveness of Paxalisib and contribute to Kazia's growth.

What Are KZIA's Competitive Advantages?

• Patented drug candidates provide exclusivity.
• Brain-penetrant technology offers a competitive advantage in treating brain cancers.
• Clinical data supporting the efficacy and safety of its drug candidates.
• Strategic partnerships with larger pharmaceutical companies.

What Does KZIA Do?

Kazia Therapeutics Limited, founded in 1994 and based in Sydney, Australia, is a biotechnology company dedicated to the development of novel anti-cancer drugs. Originally incorporated as Novogen Limited, the company rebranded to Kazia Therapeutics in November 2017 to reflect its refined strategic focus on oncology. The company's lead development candidate is Paxalisib, a small molecule designed to penetrate the brain and inhibit the PI3K/Akt/mTor pathway, a critical signaling network implicated in cancer cell growth and survival. Paxalisib is being developed as a potential therapy for glioblastoma, an aggressive form of brain cancer with limited treatment options. In addition to Paxalisib, Kazia is also advancing EVT801, an investigational new drug targeting various forms of cancer. Kazia operates with a lean team of 9 employees, reflecting a capital-efficient approach to drug development. The company's strategy involves identifying and developing promising drug candidates with the potential to address significant unmet needs in oncology. Kazia aims to create value through clinical development, strategic partnerships, and potential commercialization of its drug candidates.

What Products and Services Does KZIA Offer?

• Develops anti-cancer drugs focused on oncology.
• Focuses on small molecule, brain-penetrant inhibitors.
• Develops Paxalisib as a potential therapy for glioblastoma.
• Investigates EVT801 as a new drug for various forms of cancer.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks strategic partnerships to accelerate drug development and commercialization.

How Does KZIA Make Money?

• Develops and patents novel anti-cancer drugs.
• Conducts preclinical and clinical research to evaluate drug candidates.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Seeks regulatory approvals for its drug candidates.

What Industry Does KZIA Operate In?

Kazia Therapeutics operates within the highly competitive biotechnology industry, which is characterized by intense research and development, stringent regulatory requirements, and a high degree of risk. The company focuses on oncology, a therapeutic area with significant unmet needs and substantial market opportunities. Kazia competes with both large pharmaceutical companies and smaller biotechnology firms in the development of novel cancer therapies. Companies like BDRX, CANF, CMND, CNSP, and GRI represent the competitive landscape.

Who Are KZIA's Key Customers?

• Patients with cancer, particularly glioblastoma.
• Oncologists and other healthcare professionals.
• Pharmaceutical companies interested in licensing or acquiring drug candidates.

Kazia Therapeutics Limited Financial Trajectory

Kazia Therapeutics Limited (KZIA) reported $0 in revenue for Q2 FY2026, a decline of 100.0% compared to the prior quarter. The company recorded a net loss of $8.8M, with diluted EPS of $-2.83. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, KZIA averaged $-9.66 in diluted EPS.

Company Profile

Kazia Therapeutics Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sydney, AU. The company is led by CEO John Friend. KZIA has traded publicly since 1999.

How Kazia Therapeutics Limited Is Valued

Kazia Therapeutics Limited carries a market capitalization of $17.7M, placing it in the micro-cap category. Analyst price targets span from $25.00 to $40.00, with a consensus of $31.50. At the current price of $10.94, that implies approximately 188% upside potential. Relative to its peer group, KZIA's quantitative score of 20/100 is below the peer average of 66/100.

Key Financial Metrics

Return on assets is -31.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -32.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.87 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -40.7%, the inverse of the P/E and a quick read on earnings relative to price.

Kazia Therapeutics Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.64 places it in the distress zone, a signal of elevated financial risk.

Kazia Therapeutics Limited has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1827.8% below estimates on average.

Over the past six months, Kazia Therapeutics Limited insiders filed 2 SEC Form 4 transactions — 0 sales and 2 purchases. On net that is roughly 450K shares acquired (about $7.4M) — insiders putting money in tends to read as conviction.

KZIA Financials

KZIA Latest News

KZIA Analyst Consensus

KZIA MoonshotScore

What Investors Ask About Kazia Therapeutics Limited (KZIA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources